A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

Inclusion Criteria:

• Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression
• Previously treated with at least 1 tyrosine kinase inhibitor (TKI)
• Measurable disease
• Eastern Cooperative Oncology Group performance status 0 or 1
• Adequate lung and renal function

Exclusion Criteria:

• Prior treatment with anti-CD70-directed therapy
• Received more than one prior treatment with an mTOR inhibitor